ProfusaPFSA -16.54%8 3-Year ROIIC % is 85.05 as of Dec. 2025, which is 51% above its 10-year median of 56.40. GuruFocus rates PFSA with a GF Score™ of 8/100. The stock has 3 warning signs investors should review. Among 797 Medical Devices & Instruments companies, Profusa ranks better than 88.33% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Profusa's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 85.05%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Profusa's 3-Year ROIIC % or its related term are showing as below:
PFSA's 3-Year ROIIC % is ranked better than 88.33% of 797
companies
in the Medical Devices & Instruments industry
Industry Median: 1.47
vs PFSA: 85.05
Profusa (NAS:PFSA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Profusa 3-Year ROIIC % Related Terms
Profusa 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Profusa's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PFSA vs ODYY, SSKN, NUMD: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Profusa's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profusa 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profusa's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Profusa's 3-Year ROIIC % falls into.
Profusa's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -27.706 (Dec. 2025) - -9.443 (Dec. 2022) )
/
( 11.015 (Dec. 2025) - 32.487 (Dec. 2022) )
=
-18.263
/
-21.472
=
85.05%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Profusa (PFSA) has a 3-Year ROIIC % of 85.05 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Profusa and its competitors. This is 51% above median its historical median of 56.40. Over the past decade, Profusa's 3-Year ROIIC % has ranged from 27.75 to 85.05. According to the industry distribution chart, Profusa ranks #93 out of 797 companies in the Medical Devices & Instruments industry, placing it in the top 11.7%.
Is Profusa's 3-Year ROIIC % too high?
Profusa's current 3-Year ROIIC % of 85.05 is 51% above median its 10-year median of 56.40. Over the past 10 years, this metric has ranged from a low of 27.75 to a high of 85.05. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.47. Profusa's value of 85.05 is 5685.7% above this industry median. Based on the distribution chart, Profusa ranks #93 out of 797 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Profusa has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Profusa's 3-Year ROIIC % compare to ODYY and SSKN?
According to the Medical Devices & Instruments industry distribution chart, Profusa ranks #93 out of 797 companies for 3-Year ROIIC %. This places Profusa in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.47. Profusa's value of 85.05 is 5685.7% above this benchmark. Historically, Profusa's own 3-Year ROIIC % has ranged from 27.75 to 85.05 over the past decade. While the company's 10-year median is 56.40 vs. the industry median of 1.47, Profusa has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.47, based on 797 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profusa's current 3-Year ROIIC % of 85.05 is 5685.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Profusa and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profusa's current 3-Year ROIIC % is 85.05, which is 51% above median its own 10-year median of 56.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profusa stock overvalued right now?
Profusa (PFSA) has a current 3-Year ROIIC % of 85.05. The current 3-Year ROIIC % is 85.05, which is 51% above median its 10-year median of 56.40 and 5685.7% above the Medical Devices & Instruments industry median of 1.47. Profusa's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Profusa (PFSA), the current 3-Year ROIIC % is 85.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
8GF Score
Get the complete analysis for PFSA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PFSA has been successfully added to your 
